2020 top stories in kidney cancer

This article summarises the key breakthroughs in the treatment of renal cell carcinoma (RCC) in 2020, including a new first-line VEGF-TKI and immunotherapy combination (cabozantinib plus nivolumab) and immunotherapy as a new standard of treatment for patients with non−clear cell RCC and sarcomatoid RCC. Read more in Practice Update here Watch a video interview on […]

read more

IKCS 2020: Treatment selection in kidney cancer

During this interview, Dr Rana McKay from the University of California in San Diego gives a succinct overview of the 19th Annual Meeting of the International Kidney Cancer Symposium (IKCS 2020), including highlights from the meeting. She also discussed the effects of delaying surgery for patients with low stage (T1 and T2) renal cell carcinoma […]

read more

HIF2α inhibitor provides significant clinical benefit in patients with VHL kidney cancer

One of the major breakthroughs this year the hypoxia-inducible factor (HIF)-2α inhibitor: MK6482 for von Hippel-Lindau (VHL) disease–related clear cell renal cell carcinoma (RCC). VHL disease is a hereditary disease that affects many organs of the body, such as the eyes, brain, spine, pancreas, kidneys and lymphatic system. It is caused by a mutation in […]

read more

Future for VHL kidney cancer is bright

Von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) has always been difficult to treat. However, a group of researchers led by Dr William G. Kaelin Jr from the Dana-Faber Cancer Institute and Harvard Medical School in America have discovered treatments including immunotherapy, HIF-2α inhibitors, and potentially CDK4/6 inhibitors for the treatment of VHL-associated RCC. He […]

read more

ESMO Virtual 2020: HIF-2a MK-6482 in Von Hippel-Lindau Disease and kidney cancer

At the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Dr Cristina Suarez from the Hospital Universitari Vall D’Hebron and Vall D’Hebron Institute of Oncology in Barcelona, Spain presented an update of the clinical data from the phase 2 study of oral HIF-2a MK-6482 in Von Hippel-Lindau disease-associated cancers. Von Hippel-Lindau disease is a […]

read more

ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer

Results from a phase II international trial led by researchers at MD Anderson Cancer Center in America were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The trial showed treatment with a novel hypoxia inducible factor (HIF)-2 alpha inhibitor (MK-6482) was well tolerated and resulted in clinical responses in patients with von […]

read more

Novel HIF-2a inhibitor for patients with advanced kidney cancer

In this interview with Practice Update, Dr Eric Jonasch from MD Anderson Cancer Center in the USA talks about the the novel hypoxia inducible factor (HIF)-2 alpha inhibitor for the treatment of previously treated advanced renal cell carcinoma (RCC). Dr Jonasch described how HIF-2 alpha works and then went on to talk about the results […]

read more

ASCO GU 2020: Randomised clinical trial of HIF-2α inhibitor in patients with advanced kidney cancer

A randomised clinical trial of hypoxia inducible factor 2α (HIF-2α) inhibitor, MK-6482, was announced at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. HIF-2α is known to stimulate the growth of tumours via the von Hippel-Lindau (VLH) group of genes. MK-6482 (also known as PT2977) blocks the […]

read more

VHL disease and HIF-2alpha inhibitor

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center in Houston, Texas, USA speaks about the use of  hypoxia-inducible factor (HIF) 2alpha inhibitor for the treatment of renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease. Firstly, Dr Jonasch describes how HIF-2alpha combines with HIF-1beta to act as a transcription factor […]

read more

ESMO 2019: First in human study of HIF-2α inhibitor in patients with advanced kidney cancer

Results from the first in human study of the HIF-2α inhibitor, PT2977 in patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Hypoxia inducible factor 2α (HIF-2α) is known to stimulate the growth of tumours via the von Hippel-Lindau (VLH) group of genes. PT2977 […]

read more
Showing 1 to 10 of 13 results
  TOP